Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Hokuyaku Takeyama Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hokuyaku Takeyama Holdings ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Hokuyaku Takeyama Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where Hokuyaku Takeyama Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Hokuyaku Takeyama Holdings (SSE:3055) has a ROE % of 1.68% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Hokuyaku Takeyama Holdings and its competitors. This is 58% below median its historical median of 3.99. Over the past decade, Hokuyaku Takeyama Holdings' ROE % has ranged from 2.08 to 5.10. According to the industry distribution chart, Hokuyaku Takeyama Holdings ranks #79 out of 113 companies in the Medical Distribution industry, placing it in the top 69.9%.
Is Hokuyaku Takeyama Holdings' ROE % too high?
Hokuyaku Takeyama Holdings' current ROE % of 1.68% is 58% below median its 10-year median of 3.99. Over the past 10 years, this metric has ranged from a low of 2.08 to a high of 5.10. The Medical Distribution industry median ROE % is 7.15. Hokuyaku Takeyama Holdings' value of 1.68% is 76.5% below this industry median. Based on the distribution chart, Hokuyaku Takeyama Holdings ranks #79 out of 113 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Hokuyaku Takeyama Holdings has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hokuyaku Takeyama Holdings' ROE % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Hokuyaku Takeyama Holdings ranks #79 out of 113 companies for ROE %. This places Hokuyaku Takeyama Holdings in the lower half of its industry. The industry median ROE % is 7.15. Hokuyaku Takeyama Holdings' value of 1.68% is 76.5% below this benchmark. Historically, Hokuyaku Takeyama Holdings' own ROE % has ranged from 2.08 to 5.10 over the past decade. While the company's 10-year median is 3.99 vs. the industry median of 7.15, Hokuyaku Takeyama Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.15, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hokuyaku Takeyama Holdings's current ROE % of 1.68% is 76.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Hokuyaku Takeyama Holdings and its competitors. For the Medical Distribution industry, the median ROE % is 7.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hokuyaku Takeyama Holdings's current ROE % is 1.68%, which is 58% below median its own 10-year median of 3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hokuyaku Takeyama Holdings stock overvalued right now?
Based on GuruFocus' analysis, Hokuyaku Takeyama Holdings (SSE:3055) is currently considered Fairly Valued. The stock's GF Value™ is 円956.39, compared to a current price of 円912.00 — trading 4.6% below its estimated fair value. The current ROE % is 1.68%, which is 58% below median its 10-year median of 3.99 and 76.5% below the Medical Distribution industry median of 7.15. Hokuyaku Takeyama Holdings' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Hokuyaku Takeyama Holdings (SSE:3055), the current ROE % is 1.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hokuyaku Takeyama Holdings (SSE:3055) Overvalued in 2026?
Based on GuruFocus' analysis, Hokuyaku Takeyama Holdings stock appears to be undervalued.
The current stock price of 円912.00 is trading 4.6% below its estimated GF Value™ of 円956.39.
GuruFocus considers Hokuyaku Takeyama Holdings to be Fairly Valued.
Key valuation signals for SSE:3055:
ROE %: 1.68% (58% below median its 10-year median of 3.99)
GF Value™: 円956.39 vs. price of 円912.00 (4.6% below fair value)
Industry Position: 76.5% below the Medical Distribution median (#79 of 113)
No single metric tells the full story. See the SSE:3055 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hokuyaku Takeyama Holdings Inc is a medical device wholesaler. The company also distributes ethical drugs and general-purpose medicines. It offers repair services for medical instruments and manages real estate for physics and chemistry instruments.
56GF Score
Get the complete analysis for SSE:3055
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SSE:3055 has been successfully added to your 
